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Natural killer (NK) cells represent a pivotal player of innate anti-tumor immune responses. 
The impact of environmental factors in shaping the representativity of different NK cell 
subsets is increasingly appreciated. Human cytomegalovirus (HCMV) infection pro-
foundly affects NK  cell compartment, as documented by the presence of a CD94/
NKG2C+FcεRIγ- long-lived “memory” NK cell subset, endowed with enhanced CD16-
dependent functional capabilities, in a fraction of HCMV-seropositive subjects. However, 
the requirements for memory NK cell pool establishment/maintenance and activation 
have not been fully characterized yet. Here, we describe the capability of anti-CD20 
tumor-targeting therapeutic monoclonal antibodies (mAbs) to drive the selective in vitro 
expansion of memory NK cells and we show the impact of donor’ HCMV serostatus 
and CD16 affinity ligation conditions on this event. In vitro expanded memory NK cells 
maintain the phenotypic and functional signature of their freshly isolated counterpart; 
furthermore, our data demonstrate that CD16 affinity ligation conditions differently affect 
memory NK cell proliferation and functional activation, as rituximab-mediated low-affinity 
ligation represents a superior proliferative stimulus, while high-affinity aggregation medi-
ated by glycoengineered obinutuzumab results in improved multifunctional responses. 
Our work also expands the molecular and functional characterization of memory 
NK cells, and investigates the possible impact of CD16 functional allelic variants on their 
in vivo and in vitro expansions. These results reveal new insights in Ab-driven memory 
NK cell responses in a therapeutic setting and may ultimately inspire new NK cell-based 
intervention strategies against cancer, in which the enhanced responsiveness to mAb-
bound target could significantly impact therapeutic efficacy.
Keywords: memory nK cells, cancer immunotherapy, therapeutic anti-cD20 mab, cD16, in vitro expansion
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inTrODUcTiOn
The perspective of natural killer (NK) cells as exquisitely innate 
effectors is challenged by the recent appreciation that long-lasting 
NK cell populations with enhanced effector functions may arise 
in response to environmental factors, named adaptive or memory 
NK cells (1–3).
In vivo, memory NK  cells have been identified in human 
cytomegalovirus (HCMV)-seropositive subjects, mainly on 
the basis of high expression levels of CD94/NKG2C activating 
receptor and CD57 terminal differentiation marker (4, 5). Recent 
studies have identified an immune-receptor tyrosine-based acti-
vation motif (ITAM)-bearing FcεRIγ adaptor protein-deficient 
(FcεRIγ−) NK  cell subset in HCMV-seropositive individuals, 
endowed with a specific epigenetic signature and mostly over-
lapping with the CD94/NKG2Chigh population (6–10). FcεRIγ 
chain deficiency thus represents the hallmark of memory NK cell 
population, together with variable loss of Syk and EAT2 signaling 
intermediates, low amount of the pro-myelocytic leukemia zinc 
finger (PLZF) transcription factor, and a distinctive genome-wide 
methylation profile similar to that of memory effector T  cells 
(8, 9). As a consequence of FcεRIγ deficiency, memory NK cells 
exhibit lower surface levels of FcεRIγ-dependent NKp46 and 
NKp30 activating receptors, with respect to FcεRIγ+ conventional 
NK cells (1, 6).
Memory NK cells can constitute up to 70% of the total NK cell 
population in HCMV-seropositive individuals. The mechanistic 
basis of their selective expansion is incompletely understood. 
It has been proposed that primary HCMV infection drives the 
priming and proliferation of memory NK  cells in a NKG2C-
dependent manner (1–3, 11, 12). Such expansion may be 
maintained by a variety of different viral super-infections. In par-
ticular, an expanded population of memory NK cells was detected 
in EBV-, HBV-, HCV-, and HIV-seropositive individuals, only 
when patients were also seropositive for HCMV (13, 14). It is 
therefore conceivable that Ab-mediated immune responses may 
drive the proliferation and maintenance of an already existing 
pool of memory NK cells, in some viral disease settings. Seminal 
in  vitro studies offered a mechanistic explanation for the role 
of virus specific Abs in sustaining memory NK cell expansion, 
establishing a pivotal role for CD16 binding to Ab-opsonized 
infected cells (8, 9).
CD16, the low-affinity Fc receptor for IgG, or FcγRIIIa, 
represents a prototype NK activating receptor; its engagement by 
IgG-opsonized targets is sufficient to trigger antibody-dependent 
cytotoxicity (ADCC), as well as the production of pro-inflam-
matory cytokines and chemokines, such as IFN-γ, TNFα, IL-6, 
GM-CSF, and CCL5 (15, 16). In particular, NK-derived IFN-γ 
stands as a well-recognized key immunoregulatory factor in the 
shaping of anti-tumor adaptive immune responses, by modulat-
ing dendritic cells (DCs) and T-cell responses (17, 18). Moreover, 
the capability of CD16-initiated signals to regulate NK  cell 
proliferation and death, under selective conditions, has been also 
shown (19, 20).
Human CD16 exhibits two extracellular Ig domains, a short 
cytoplasmic tail and a transmembrane domain that enables its 
association with ITAM-containing CD3ζ and FcεRIγ chains (21), 
which guarantee Syk- and ZAP-70-dependent signal transduc-
tion (16).
Multiple lines of evidence highlighted a functional superiority 
of memory compared with conventional NK  cells, in response 
to stimulation through CD16, particularly in terms of cytokine 
production (6–8, 22). Indeed, memory NK cells exhibit a greatly 
enhanced ability to produce IFN-γ, as a consequence of hypo-
methylated IFNG regulatory region (23), in response to activa-
tion via CD16, thus providing a prompt and powerful response 
against antibody-opsonized target cells.
The exploitation of memory NK  cells in cancer combina-
tion immunotherapy may be highly attractive, because of their 
unique properties of CD16-dependent longevity and amplified 
functional responses. Indeed, CD16-triggered ADCC and phago-
cytosis, performed by NK  cells and macrophages, respectively, 
are among the main immune-dependent mechanisms by which 
therapeutic monoclonal antibodies (mAbs) mediate tumor cell 
killing (24–27). Moreover, CD16-dependent immunomodula-
tory activity may contribute to the “vaccinal effect” of therapeutic 
tumor-targeting mAbs, i.e., the promotion of adaptive anti-tumor 
immune responses that confer long-term protection (17, 18, 
28, 29). This concept is supported by the evidence that a single 
nucleotide polymorphism of the FCGR3A gene (c.559G>T, 
p.Phe158Val), encoding for a lower (FcγRIIIA-158F) or a higher 
(FcγRIIIA-158V) affinity allele of CD16 receptor, affects the clini-
cal response to rituximab anti-CD20 mAb treatment that stands 
as a well-established first-line therapeutic option in several B cell 
malignancies (30, 31). More recently, new mAbs with enhanced 
affinity for CD16 have been generated. Among them, obinutu-
zumab, recently approved for clinical use (32–34), is a type II 
glycoengineered anti-CD20 mAb with an afucosylated crystal-
lizable fragment (Fc) domain that binds to a CD20 epitope in a 
different space orientation and with a wider elbow-hinge angle 
with respect to the reference molecule rituximab (35).
Our recent data highlighted that distinct CD16 aggregation 
conditions, obtained through sustained contact with target cells 
opsonized by different anti-CD20 mAbs, differently promote the 
shift of NK cell functional program (36, 37).
Here, we address the capability of anti-CD20 mAbs to affect 
memory NK cell dynamics. We demonstrate that the co-culture 
with anti-CD20 mAb-opsonized targets selectively supports the 
in  vitro expansion of in  vivo primed memory NK  cells, which 
phenotypically and functionally mirror their freshly isolated 
counterpart. CD16 engagement under quantitatively different 
affinity ligation conditions qualitatively impacts on memory 
NK-cell responses, being rituximab more efficient in supporting 
expansion, and obinutuzumab more active in inducing functional 
activation.
We also investigate the possible impact of CD16 functional 
allelic variants on memory NK cell in vivo and in vitro expansion.
MaTerials anD MeThODs
cell systems and anti-cD20 mabs
Peripheral blood mononuclear cells (PBMCs) were freshly isolated 
from peripheral blood samples of anonymized healthy donors of 
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Transfusion Center of Sapienza University of Rome, over a Ficoll-
Hypaque (Cedarlane) density gradient. Written informed consent 
was obtained from blood donors, and both the informed consent 
form and procedure were approved by the Ethics Committee of 
Sapienza University of Rome. The study was conducted in accord-
ance with the Declaration of Helsinki. The following human cell 
lines were used as targets: Raji CD20+ lymphoblastoid, provided 
by Dr. F. D. Batista (Cancer Research UK, London), and K562 
erithroleukemia, obtained from ATCC. All cell lines were kept in 
culture for less than 2 consecutive months in 10% fetal calf serum 
(FCS)- and 1% l-glutamine (both from Euroclone)-containing 
RPMI 1640 and regularly checked for mycoplasma presence. The 
following anti-CD20 mAbs were used: the chimeric IgG1κ type I 
rituximab, the humanized IgG1κ type II glycoengineered obinu-
tuzumab (GA101), and its nonglycoengineered parental molecule 
(GA101-WT), all kindly provided by Dr. Christian Klein, Roche 
Innovation Center Zurich (Schlieren, Switzerland).
immunostaining and cytofluorometric 
analysis
Phenotypic Characterization of NK Cells
Peripheral blood-derived and in vitro cultured mononuclear cell 
populations were identified by a combination of physical parameters 
and immunostaining with saturating concentrations of the follow-
ing fluorochrome-conjugated mAbs: anti-CD3 PerCP (clone: SK7, 
cat #: 347344; BD Biosciences) or PerCP-Vio700 (clone: REA613, 
cat #: 130-109-465; Miltenyi Biotec), anti-CD56 APC (clone: B159, 
cat #: 555518; BD Biosciences) or APC-Vio770 (clone: REA 196, 
cat #: 130-100-694; Miltenyi Biotec), CD16 PE (clone: B73.1, cat #: 
347617; BD Biosciences) or PE-Vio770 (clone: REA423, cat #: 130-
106-706; Miltenyi Biotec), anti-FcεRIγ subunit FITC (polyclonal 
antibody, cat #: FCABS400F; Merck), anti-NKp46 APC (clone: 
REA808, cat #: 130-112-122; Miltenyi Biotec), anti-NKG2C PE 
(clone: 134591, cat #: FAB138P; R&D Systems), anti-PLZF PE 
(clone: Mags.21F7, cat #: 12-9320-82; ThermoFisher Scientific), 
anti-PD-1 PE (clone: EH12.2H7, cat #: 329906; BioLegend), and 
anti-PD-L1 APC (clone: 29E.2A3, cat #: 329708; BioLegend). 
Samples were stained for surface antigens for 30 min at 4°C, washed 
with PBS (Euroclone) containing 2% FCS and 2 mM EDTA (used 
for all washing steps), fixed with 2% paraformaldehyde for 20 min 
at room temperature (RT), washed, permeabilized with washing 
solution supplemented with 0.05% Triton-X 100 for 30 min at RT, 
and stained for intracellular antigens for 30 min at 4°C.
Characterization of FcγRIIIA-158V/F Allotype
The FcγRIIIA-158V/F allotype was determined on a cohort of 
217 donors, as previously described (37). Briefly, PBMCs were 
stained with APC-conjugated anti-CD56 mAb and the follow-
ing anti-CD16 mAbs: FITC-conjugated 3G8 (cat #: 555406; 
BD Biosciences) that binds to a not polymorphic epitope or 
FITC-conjugated MEM-154 (cat #: MAB-1457F; Immunological 
Science), whose binding to CD16 is dependent on the presence 
of valine (38). The ratio between the mean fluorescence intensity 
(MFI) of MEM-154 and 3G8 allows to classify the following three 
different phenotypes: F/F (ratio < 0.04), V/V (ratio > 0.62), and 
V/F (ratio between 0.15 and 0.48).
CD107a Mobilization and Intracellular IFN-γ Production
Freshly isolated PBMCs and their in vitro cultured counterparts 
were stimulated with Raji cells (2:1), opsonized or not with the 
minimum saturating dose of rituximab (1 μg/1 × 106) or obinu-
tuzumab (0.1 μg/1 × 106), or with K562 targets, for 6 h at 37°C in 
the presence of PE-conjugated anti-CD107a mAb (clone: H4A3, 
cat #: 555801; BD Biosciences) and 50 µM Monensin (Golgi-stop; 
cat #: M5273; Merck). After the first hour, 10 µg/ml Brefeldin A 
(cat #: B7651; Merck) was added. At the end of stimulation, cells 
were washed with 5 mM EDTA containing PBS and then stained 
as earlier, adding the anti-IFN-γ APC (clone: B27, cat #: 554702; 
BD Biosciences) after permeabilization.
Samples were analyzed with a FACSCanto II (BD), and data 
were obtained with FlowJo vX.0.7 (TreeStar) software. Where 
required, twin samples were added and stained with isotype 
control mAb, used to set the threshold for antigen positivity. The 
values of cell counts and cytofluorimetric analysis percentages 
were used to obtain the absolute number of different NK  cell 
subsets.
In Vitro nK cell culture
Freshly isolated PBMC from healthy donors were seeded in 
round-bottomed 96-well plates (50,000 cells/well) and cultured 
for 10  days in RPMI 1640 medium supplemented with 10% 
FCS, 1% l-glutamine, 1% penicillin/streptomycin, and 100 U/
ml of human recombinant IL-2 (cat #: AF-200-02; Peprotech); 
after 2  days, irradiated Raji cells (3000  rad), incubated or not 
with an excess of rituximab, obinutuzumab, or wt-obinutuzumab 
(GA101-WT) (all from Roche) for 20 min at RT, were washed 
and added to the cultures (25,000  cells/well). Recombinant 
hIL-2-containing medium (100 IU/ml) was half-replaced every 
2 days. At day 10, cells were harvested and used for phenotypic 
and functional analyses. For functional assays, 10 ng/ml of IL-15 
(cat #: AF-200-15; Peprotech) was added at day 7.
hcMV serostatus analysis
Anti-HCMV plasma IgG titers were determined by CMV IgG 
Immulite 2000 System (Siemens Healthineers), according to the 
manufacturer’s instructions.
statistical analysis
Differences between two groups were determined by two-tailed 
Mann–Whitney U test or Wilcoxon signed rank test, as appro-
priate. Analyses were performed using Prism v.6 (GraphPad 
Software) and SPSS v24.0 (IBM Italia SpA) software packages. 
Differences were considered to be statistically significant when p 
value was <0.05 (two sided).
resUlTs
In Vivo characterization of Memory nK 
cell compartment: impact of Fcgr3a-
V158F Polymorphism
Our analysis of an extended cohort of 275 healthy donors evi-
denced that a discrete memory NK  cell population, identified 
as CD3-CD56dimCD16+FcεRIγ− (Figure  1A), and accounting 
FigUre 1 | In vivo characterization of human memory natural killer (NK) cells. (a) Gating strategy for the identification of CD3−CD56dimCD16+FcεRIγ− memory 
NK cells. (B) Percentage of memory NK cells (with respect to total NK cells) in the peripheral blood of human cytomegalovirus (HCMV) seropositive (HCMV+) and 
seronegative (HCMV−) healthy donors; dotted line marks the value of 3%. (c) Percentage of total CD3−CD56+ NK cells among peripheral blood mononuclear 
leukocytes, in the same individuals. (D) Percentage of memory NK cells (with respect to total NK cells) in the peripheral blood of HCMV+ healthy donors, stratified 
according to CD16 allotype; dotted line marks the value of 3%. (e) Percentage of total CD3−CD56+ NK cells among peripheral blood mononuclear leukocytes, in the 
same individuals. CD16 mean fluorescence intensity (MFI) on memory (F) and total (g) NK cells of HCMV+ healthy donors, stratified according to CD16 allotype. 
Bars represent median and 10–90 percentiles. p values of pairwise comparisons are from Mann–Whitney non-parametric test.
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for more than 3% of total CD3-CD56+ NK cells, was present in 
52.4% of individuals (data not shown). In line with the literature 
(8–10), the presence of memory NK  cells strictly correlated 
with HCMV seropositivity, as shown in serotyped individuals 
(Figure  1B). On the contrary, the percentage of total NK  cells 
in HCMV-seropositive and -seronegative individuals was not 
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significantly different (Figure 1C). FcεRIγ− cells expressed other 
markers previously associated to memory NK cell profile (6, 8, 9): 
the percentage of NKG2C+ cells was higher whereas the fraction 
of NKp46+ cells was lower, with respect to the FcεRIγ+ counter-
part. Moreover, PLZF transcription factor and CD16 expression 
levels were significantly lower in memory with respect to con-
ventional NK cells (Figures S1A–D in Supplementary Material). 
Additionally, memory NK cells expressed PD-L1 at significantly 
lower levels than their conventional counterpart (Figure S1E in 
Supplementary Material).
It has been proposed that in  vivo maintenance of a long-
lasting memory NK cell population relies on CD16-dependent 
interaction with antiviral Ab-opsonized infected cells (7, 9). 
In order to analyze the impact of CD16 affinity for IgG on the 
in vivo development of memory NK cell compartment, HCMV+ 
individuals were stratified on the basis of CD16 allotype: V/V 
(homozygous for high-affinity allele, 29 donors), F/F (homozy-
gous for low-affinity allele, 29 donors), and V/F (45 donors). 
The percentage of total NK  cells and that of memory NK 
population were not significantly different among individuals 
bearing different CD16 allotypes (Figures 1D,E), although V/V 
donors displayed a tendentially reduced frequency of memory 
NK cells (Figure 1D). Notably, both memory (Figure 1F) and 
total (Figure 1G) NK cells of V/V donors expressed lower levels 
of CD16 receptor, with respect to F/F donors. Nevertheless, 
the reduced CD16 levels of memory NK  cells with respect to 
conventional NK cells (Figure S1A in Supplementary Material) 
were maintained across the three CD16 allotypes (Figure S2 in 
Supplementary Material).
anti-cD20-Mediated cD16 ligation 
induces the selective In Vitro expansion 
of Memory nK cells: impact of hcMV 
seropositivity status and cD16 affinity 
ligation conditions
Previous work has demonstrated that in  vitro expansion of 
memory NK cells critically requires Ab-opsonized virus-infected 
cells (7, 9). In order to assess whether therapeutic tumor-targeting 
mAbs may drive memory NK  cells expansion, we co-cultured 
healthy donor PBMC that displayed a sizeable population of 
memory (>3% of NK cells), with Raji lymphoblastoid B cell line, 
opsonized or not with rituximab anti-CD20 mAb, in the pres-
ence of IL-2 (Figure 2A). While conventional NK cells efficiently 
underwent expansion (up to 50-fold, Figure 2C), independently 
from rituximab, memory NK  cells proliferated much more 
markedly in the presence of rituximab (4.6–76.3-fold) than in 
its absence (0.1–16.7-fold) (Figure 2B), indicating an antibody 
requirement to support memory NK cell expansion.
In order to assess whether these in  vitro culture conditions 
could promote memory NK cell generation, or rather amplify a 
pre-existing memory NK cell pool driven by in vivo HCMV expo-
sure, we assayed memory NK cell expansion dynamics in donors 
that lacked a sizeable memory population (less than 3% of total 
NK cell population), obtained from either HCMV-seropositive 
and -seronegative individuals. Memory NK cells more vigorously 
proliferated in the presence of rituximab than in its absence, 
when derived from HCMV+ donors. At variance, rituximab 
addition did not appreciably affect in vitro expansion of memory 
NK cells from HCMV-seronegative individuals (Figure 2D). No 
significant differences in the extent of conventional NK cell sub-
set proliferation were observed between HCMV+ and HCMV− 
samples, either in the presence or in the absence of rituximab 
(Figure 2E).
Collectively, these data indicate that memory NK cells selec-
tively expand in  vitro in a rituximab-dependent manner and 
that such response critically requires a previous HCMV in vivo 
priming.
We then compared three anti-CD20 mAbs, endowed with 
low [rituximab or obinutuzumab wild-type, fucosylated parental 
mAb (GA101-WT)] or high (obinutuzumab) binding affinity for 
CD16, for their ability to drive memory NK cell proliferation; in 
this system, we could dissect the impact of FcR binding affinity 
from that of targeted epitope and binding orientation on CD20 
molecule. Rituximab was markedly more efficient in inducing the 
expansion of memory NK cells, as compared with obinutuzumab; 
Fc glycoengineering only partially accounted for such difference, 
since the expansion capability of GA101-WT was intermediate, 
suggesting that factors other than CD16 affinity may impact 
on memory NK  cell expansion (Figure  3A). Moreover, as 
conventional NK  cell proliferation was negatively affected by 
obinutuzumab, it is possible that signals arising under high CD16 
affinity ligation conditions may interfere with NK cell expansion 
(Figure  3B). However, T-cell proliferation was not negatively 
affected by obinutuzumab presence, in the same samples (data 
not shown).
Memory NK  cells expressing all CD16 allotypes expanded 
in response to rituximab, with higher levels in low-affinity F/F, 
with respect to V/F individuals. Furthermore, obinutuzumab 
resulted less efficient in inducing memory NK cell proliferation 
independently from CD16 allotype, confirming its ability to over-
come the affinity ligation differences due to CD16 polymorphism 
(Figure 3C).
Phenotypic and Functional Profile of 
In Vitro expanded Memory nK cells
Consistent with what observed in the freshly isolated popula-
tion (Figure S1 in Supplementary Material), in  vitro cultured 
memory NK cells displayed a lower percentage of NKp46+ cells, 
as compared to FcεRIγ+ conventional population; the frequency 
of NKG2C+ memory NK cells remained significantly higher with 
respect to conventional ones; and similar to what observed in 
freshly isolated samples, the expression levels of PLZF transcrip-
tion factor and CD16 were lower in cultured memory NK cells, as 
compared to conventional NK cells (Figures 4A–D). However, it 
must be noted that the expression of all these markers underwent 
marked modulation upon in vitro culture, on both memory and 
conventional NK cell subsets (compared with the respective pan-
els of Figure S1 in Supplementary Material). Interestingly, PD-L1 
expression stably remained on a low percentage of memory 
NK cells, while significantly declined on conventional NK cells, 
upon in vitro expansion (Figure 4E; Figure 1E in Supplementary 
Material).
FigUre 2 | In vitro memory natural killer (NK) cell expansion upon interaction with rituximab-opsonized Raji lymphoblastoid cells. (a) Experimental setting  
of NK cell co-culture protocol. (B) Memory (FcεRIγ−) and (c) conventional (FcεRIγ+) CD3−CD56dimCD16+ NK cell numbers (per million mononuclear cells), at  
the start (day 0) and at the end (day 10) of co-culture with Raji cells, opsonized (RTX) or not (Ctrl) with rituximab anti-CD20 monoclonal antibody (mAb).  
(D) Memory (FcεRIγ−) and (e) conventional (FcεRIγ+) NK cell fold increase from individuals with less than 3% of memory NK cells. Donors were stratified  
according to human cytomegalovirus (HCMV) seropositivity status. Dotted line marks the value of 1. p values of pairwise comparisons are from Wilcoxon  
and Mann–Whitney non-parametric tests, as appropriate.
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The ability to mediate enhanced functional responses to Ab 
stimulation, particularly in terms of IFN-γ production, is a well-
established characteristic of memory NK cells (6, 7, 9, 22).
We assessed memory NK cell responsiveness to CD16 or to direct 
target stimulation. In freshly isolated populations, upon CD16 
stimulation obtained with rituximab or obinutuzumab-opsonized 
targets, the frequency of memory NK cells able to mediate both 
degranulation and IFN-γ production was significantly higher with 
respect to the conventional counterpart. Notably, obinutuzumab-
mediated stimulation resulted more efficient in the induction of 
multifunctional responses in both memory and conventional 
NK cells, with respect to rituximab stimulation (Figure 5A).
FigUre 3 | Effect of CD16 affinity ligation conditions on memory natural killer (NK) cell in vitro expansion from HCMV+ individuals. (a) Memory (FcεRIγ−) and (B) 
conventional (FcεRIγ+) CD3−CD56dimCD16+ NK cell fold increase, in response to the presence of Raji opsonized, or not (Ctrl), with rituximab (RTX), glycoengineered 
obinutuzumab (OBZ), or wild-type OBZ (GA101-WT). (c) Memory NK cell fold increase in response to rituximab or glycoengineered OBZ in samples stratified 
according to donor’s CD16 allotype; Only statistically significant comparisons are depicted. Donors reported in Figures 2B–c are included. p values of pairwise 
comparisons are from Wilcoxon and from Mann–Whitney non-parametric tests, as appropriate.
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Basal responsiveness of in  vitro expanded NK  cells was 
enhanced, as a consequence of the exposure to IL-2 plus IL-15 
during the last 3 days of culture. In these conditions, obinutu-
zumab-mediated stimulation was able to induce a significantly 
higher response rate in memory with respect to conventional 
NK cells (Figure 5B). Differently, memory NK cell responses to 
rituximab-coated target cells were only tendentially higher than 
conventional NK cells, possibly in dependence on the markedly 
low CD16 expression level (see Figure  4A). Furthermore, in 
line with the literature and similarly to what observed on their 
fresh counterparts, mAb-expanded cultured memory NK  cells 
displayed a defective ability to respond to K562 target cells (6).
DiscUssiOn
Natural killer cell’s role in tumor immunosurveillance, as well 
as their involvement in immune-dependent therapeutic efficacy 
of tumor-targeting mAbs, is widely recognized (27, 39). NK cell 
functional and phenotypic heterogeneity, together with the 
recent identification of a long-lived and hyper-responsive subset, 
named adaptive or memory, have raised much interest, to the end 
of a better exploitation of this anti-tumor effector in the develop-
ment of innovative combination immunotherapeutic strategies.
The present work provides a further characterization 
of freshly isolated human memory NK  cells, identified as 
CD3−CD56dimCD16+ FcεRIγ−, and defines the ability of therapeu-
tic mAb-coated tumor cells to efficiently drive their in vitro expan-
sion from HCMV-seropositive healthy donors’ PBMC. Indeed, 
we developed an effective in vitro culture system, consisting of 
a 10-day co-culture of PBMC with irradiated lymphoblastoid 
Raji cells opsonized with anti-CD20 mAbs, in IL-2-containing 
medium. Our results demonstrate the strict dependence of 
memory NK  cell proliferation on the presence of opsonizing 
mAb, as their expansion in the presence of not opsonized targets 
was only marginal. These data strongly support the concept 
that CD16-initiated signals are crucially involved in triggering 
FigUre 4 | Phenotypic characterization of in vitro cultured human memory natural killer (NK) cells. CD16 mean fluorescence intensity (MFI) (a), frequency of 
NKG2C+ (B), and of NKp46+ (c) cells, pro-myelocytic leukemia zinc finger (PLZF) MFI (D), and percentage of PD-L1+ (e) cells, were evaluated on memory (FcεRIγ−) 
and conventional (FcεRIγ+) CD3−CD56dimCD16+ NK cells, upon co-culture with rituximab-opsonized Raji cells. p values of pairwise comparisons are from Wilcoxon 
non-parametric test.
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the proliferation of this specific subset. In accordance, previous 
evidence had shown the capacity of anti-viral IgG-opsonized 
cells to induce memory NK cells proliferation (8, 9). Differently, 
conventional NK cells were capable of effectively and comparably 
expand upon co-culture with either not opsonized or therapeutic 
mAb-coated feeder cells, thus suggesting that cell–cell interac-
tions with surface ligands expressed by Raji lymphoma cells, 
together with cytokines, provide sufficient proliferative signals to 
them. Indeed, the capability of EBV+ lymphoblastoid cell lines to 
induce NK cell proliferation has been widely reported (40), and 
the crucial role of 2B4/CD48 interaction in this context has been 
recently proposed (41). Moreover, CD16-dependent NK  cell 
proliferation has been recently reported, in a 21-day culture pro-
tocol under selected co-stimulation conditions, but no evaluation 
of the memory NK cell compartment was performed (20). It is 
conceivable that CD16-dependent memory NK cell proliferation 
also relies on multiple accessory signals, conveyed by cell–cell 
contacts and soluble mediators; in this context, the synergistic 
effect of antisera and virus-infected cells was reported (8, 9). 
In our system, ligands expressed by Raji lymphoblastoid B cells 
may provide accessory proliferative signals to memory NK cells; 
among them, CD2 ligand, CD58, has been shown to co-stimulate 
memory NK  cell responses (22). Moreover, monocyte-derived 
IL-12, probably stimulated through FcγR engagement by anti-
CD20-opsonized targets, likely mediates a critical contribution 
through the up-regulation of CD25, as demonstrated by a recent 
report (12).
Our results identify donor HCMV-seropositive status as a 
prerequisite to allow anti-CD20 mAb-dependent memory NK cell 
in vitro expansion. In fact, in vitro memory NK cell proliferation 
could be obtained from HCMV+, but not from HMCV− donors 
that in  vivo lacked a sizeable (>3% of total NK  cells) memory 
NK  cell population. These data suggest that HCMV exposure 
is indispensable for the priming of a memory NK cell pool and 
are in accordance with multiple lines of evidence that have dem-
onstrated the unique ability of HCMV to epigenetically shape a 
NKG2C+ memory NK compartment, and the capability of viral 
reactivation to promote a long-lasting expansion of the memory 
NK cell pool (1–5). Furthermore, in vitro expansion of NKG2C+ 
memory NK  cells could be achieved by co-culturing NK  cells 
with HCMV-infected fibroblasts or HLA-E-expressing feeder 
(11, 12, 42). In these conditions, the interaction between the 
activating receptor CD94/NKG2C and its cellular ligand HLA-E, 
in combination with inflammatory cytokines, was critical for 
their expansion.
As a consequence of the lack of FcεRIγ chain, and in line with 
previous reports (6, 12), we found that freshly isolated memory 
NK  cells displayed lower levels of FcεRIγ-coupled activating 
receptors, such as NKp46 and CD16, and of PLZF transcription 
factor, whose deficiency is responsible for the silencing of FcεRIγ 
FigUre 5 | Functional responsiveness of fresh and in vitro cultured memory 
natural killer (NK) cells. Fresh (a) and cultured (B) memory (filled symbols) 
and conventional (empty symbols) NK cells were stimulated as indicated, and 
the percentage of CD107a/+IFN-γ+ was evaluated by immunostaining and 
FACS analysis. p values of pairwise comparisons are from Wilcoxon 
non-parametric test.
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gene (8), as compared to their conventional counterpart; moreo-
ver, as previously reported (4, 10, 11), NKG2C+ cells were more 
abundant within memory NK cell pool. Although the expression 
of these markers was dramatically modulated upon in vitro culture, 
their distinctive expression pattern on memory vs conventional 
NK  cells was remarkably maintained. Interestingly, our results 
identify the lower expression of PD-L1, ligand of PD-1 immune 
checkpoint, as another distinctive feature of freshly isolated 
memory NK cells, as compared with conventional counterpart. 
In this regard, although the presence of PD1+ NK cells in a limited 
percentage of HCMV+ healthy individuals has been previously 
reported (43), the expression of PD-L1 ligand on human NK cells 
remains mostly unexplored.
Here, we have addressed the impact of CD16 affinity ligation 
on memory NK cell in vitro and in vivo expansion, and functional 
activation. We observed that CD16F158V polymorphism dictat-
ing receptor binding affinity for Ab Fc region (30, 31) does not affect 
the frequency of memory NK cells in vivo, in an extended cohort 
of CD16 genotyped individuals. Nevertheless, CD16 expression 
levels on either total NK cells or memory NK cell fraction were 
higher in low (F/F) with respect to high (V/V) affinity individuals, 
probably as a consequence of a reduced rate of Ab-induced CD16 
internalization. Interestingly, in vitro memory NK cell expansion 
was heavily affected by CD16 ligation conditions promoted by 
anti-CD20 therapeutic mAbs. In fact, rituximab, a low-affinity 
ligand for CD16, much more efficiently drove memory NK cell 
expansion than obinutuzumab, whose glycoengineering allows a 
high-affinity interaction with the receptor. The lower capability 
of obinutuzumab to trigger memory NK  cell proliferation was 
maintained across all CD16 allotypes, in accordance with its 
capacity to overcome polymorphism-dependent CD16 affinity 
differences (37, 44). Along this line, the rate of memory NK cell 
expansion in response to rituximab was superior in F/F low-
affinity homozygous with respect to V/F donors, suggesting that 
their proliferation may benefit from a low-affinity CD16 ligation.
Proliferation of both memory and conventional NK  cells 
was negatively affected by the presence of obinutuzumab, when 
compared with rituximab reference mAb. These data suggest 
that ligation conditions alter the balance between cell death 
and proliferation stimulated by CD16 cross-linking. Indeed, 
the capability of CD16-induced signals to induce apoptosis in 
NK  cells has been earlier reported (19, 45). Such observation 
may offer an explanation for the protracted reduction of circulat-
ing NK cell levels observed in obinutuzumab-receiving patients 
(46). Moreover, these data imply that CD16-generated signaling 
pathways, although not necessary to drive their in vitro expan-
sion, may also operate in conventional NK cells. Co-culture with 
non-glycoengineered obinutuzumab (GA101-WT)-opsonized 
targets only partially restored memory NK cell expansion ability, 
suggesting that other factors than higher affinity for CD16 are 
responsible for obinutuzumab reduced ability to support mem-
ory NK cell proliferation. Indeed, as a class II mAb, it is endowed 
with a reduced capacity to induce CD20 down-regulation on 
target cells and a higher capability to induce direct target cells 
death (47) that could impact stimulation efficiency. However, it 
is also possible that different CD16 affinity ligation conditions 
impact on memory NK cell expansion kinetics.
A key feature of memory NK  cells is their superior 
Ab-dependent functional response, with respect to conventional 
ones (6–9, 22). Indeed, despite the lower CD16 expression, they 
have been shown to more efficiently mediate multifunctional 
responses, i.e., degranulation and IFN-γ production, upon stimu-
lation via ADCC. This characteristic is confirmed by our data, as 
either freshly isolated or in vitro cultured memory NK cells dis-
played a higher frequency of multifunctional (IFN-γ+CD107a+) 
cells, upon triggering with anti-CD20-opsonized target cells. The 
apparent conflict between higher CD16-triggered functional 
responses and lower surface receptor levels may be explained 
by the exclusive coupling of CD16 to CD3ζ chain in memory 
NK cells that, thanks to ITAM motif quantitative differences (3 
ITAM in CD3ζ vs 1 ITAM in FcεRIγ), may lead to more robust 
and efficient biochemical signals (15). Moreover, the residual 
levels of CD3ζ chain may preserve the CD2/CD58 co-stimulatory 
interaction (48).
Interestingly, stimulation with obinutuzumab-coated targets 
promoted a more efficient activation of either fresh or in  vitro 
expanded memory NK cells and led to enhanced degranulation 
and IFN-γ production, with respect to rituximab. The enhanced 
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obinutuzumab-triggered response, as expected, was also observed 
in conventional NK cell populations. These data highlight a signal 
dichotomy downstream of CD16 engagement, being the high-
affinity ligation an added value for functional activation and the 
low affinity useful for proliferative signals. The reduction of NKp46 
levels may explain the reduced ability of fresh and in vitro cultured 
memory NK cell to mediate effector functions in response to stim-
ulation with K562 target cell, being its recognition largely dependent 
on this receptor (49). However, NKG2C+ memory NK cells from 
HCMV-reactivating patients efficiently produced IFN-γ upon 
K562 stimulation (5, 50), indicating that the up-regulation of other 
activating receptors may compensate for the NKp46 defect.
In conclusion, we add new insights on the molecular factors 
governing the expansion and activation of memory NK cells. In 
a therapeutic perspective, they represent a particularly attractive 
tool of cancer immunotherapy, especially in mAb-based regi-
mens where the enhanced responsiveness to mAb-coated targets 
could significantly impact therapeutic efficacy. These results may 
guide future attempts to combine the adoptive transfer of ex vivo 
expanded memory NK cells, or their in vivo manipulation, with 
therapeutic mAb administration.
Finally, it is worth investigating the possible contribution 
of this long-lived NK  cell population to the recently described 
“vaccinal effect” of therapeutic mAbs. Indeed, thanks to their 
amplified capability to produce cytokines upon CD16 stimula-
tion, memory NK cells could participate to the development of 
adaptive anti-tumor immune responses, required for the long-
term protection of treated patients (27–29).
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